Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion

• Status: Recruiting
• Trial end date: 2024-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this investigation is to compare the efficacy of two different antithrombotic strategies after percutaneous LAA occlusion with a Watchman device on the prevention of silent cerebral embolism.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
• Collaborators: Jiangsu Taizhou People's Hospital; Second Affiliated Hospital of Nantong University
• Treatments: Aspirin; Clopidogrel; Rivaroxaban

Criteria

Inclusion Criteria:

1. AF patients over 18 years old

2. Patients had undergone left atrial appendage occlusion with WATCHMAN device and confirmed no significant peri-device leak or DRT at the 45-day CT

3. Patients have a history of ischemic thromboembolic events or have CHA2DS2-VASc score ≥3

Exclusion Criteria:

1. Patients with an indication of long-term antiplatelet therapy other than LAAO at the time of enrollment (eg, ACS, Intracranial vascular stenosis≥75%)

2. Absolute contraindications to OAC

3. Absolute contraindications to anti-platelet therapy

4. Contraindications to MR or unwilling to receiving MR

5. Patients with clinical thromboembolicor major bleeding events within 45 days after LAA occlusion